Pneumonia and risk of venous thrombosis: results from the MEGA study

8 Sauer WH, Berlin JA, Kimmel SE. Eff ectofantidepressantsandtheirrelative affinity for the serotonin transporter on the risk of myocardialinfarction. Circulation 2003; 108: 32–6.9 Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reup-take inhibitors and myocardial infarction. Circulation 2001; 104: 1894–8.10 Schlienger RG, Fischer LM, Jick H, Meier CR. Current use of selectiveserotonin reuptake inhibitors and risk of acute myocardial infarction.Drug Saf 2004; 27: 1157–65.11 Meier CR, Schlienger RG, Jick H. U se of selective serotonin reuptakeinhibitors and risk of developing first-time acute myocardial infarction.BrJClinPharmacol2001; 52: 179–84.12 Bak S, Tsiropoulos I, Kjaersgaard J O, Andersen M, Mellerup E, HallasJ, Rodri´guez LAG, Christensen K, Gaist D. Selective serotoninreuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke 2002; 33: 1465–73.13 Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptakeinhibitor antidepressants and abnorm al bleeding: a review for cliniciansand a reconsideration of mechanisms. J Clin Psychiatry 2009; 71: 1565–75.14 Tseng YL, Chiang ML, Huang TF, Su KP, Lane HY, Lai YC. Aselective serotonin reuptake inhibitor, citalopram, inhibits collagen-in-duced platelet aggregation and activation. Thromb Res 2010; 126: 517–23.15 Galan AM, Lopez-Vilchez I, Diaz-Ricart M, Navalon F, Gomez E,Gasto C, Escolar G. Serotonergic me chanisms enhance platelet-med-iated thrombogenicity. Thromb Haemost 2009; 102: 511–19.16 Serebruany VL, Gurbel PA, O Connor CM. Platelet inhibition bysertraline and N-desmethylsertraline: a possible missing link betweendepression, coronary events, and mortality benefits of selective seroto-nin reuptake inhibitors. Pharmacol Res 2001; 43: 453–62.17 SerebruanyVL,O ConnorCM,GurbelPA.Effectofselectiveserotoninreuptake inhibitors on platelets in patients with coronary artery disease.Am J Cardiol 2001; 87: 1398–400.18 CiprianiA,FurukawaTA,SalantiG,GeddesJR,HigginsJP,ChurchillR, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M,Barbui C. Comparative efficacy and acceptability of 12 new-generationantidepressants: a multiple -treatments meta-analysis. Lancet 2009; 373:746–58.19 vanBladelER,RoestM,deGrootPG,SchutgensRE.Up-regulationofplatelet activation in hemophilia A. Haematologica 2011; 96: 888–95.20 Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selec-tive serotonin reuptake inhibitors on human platelet serotonin. ThrombHaemost 2004; 91: 119–28.21 AtarD,MalininA,PokovA,vanZylL,Frasure-SmithN,LesperanceF, Serebruany VL. Antiplatelet prope rties of escitalopram in patientswith the metabolic syndrome: a dose-ranging in vitro study. Neuro-psychopharmacology 2007; 32: 2369–74.22 Musselman DL, Tomer A, Manatunga AK, Knight BT, Porter MR,Kasey S, Marzec U, Harker LA, Nemeroff CB. Exaggerated plateletreactivity in major depression. Am J Psychiatry 1996; 153: 1313–17.